HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice.

Abstract
Febrile neutropenia (FN) risk-assessment and granulocyte-colony stimulating factor (G-CSF) prophylaxis use in clinical practice was evaluated in patients with diffuse large B-cell lymphoma receiving R-CHOP-21. More G-CSF primary prophylaxis was used in patients assessed as high FN risk, but R-CHOP-21 was associated with substantial myelotoxicity in both high- and low-risk groups. In a multivariate analysis, older age, poor performance status, lower baseline hemoglobin, and lack of G-CSF prophylaxis were significantly associated with occurrence of FN in any cycle. Results highlight the need for improved FN risk-assessment and thorough guideline adherence to further reduce FN and better support chemotherapy delivery.
AuthorsAntonio Salar, Corinne Haioun, Francesca G Rossi, Ulrich Duehrsen, Ruth Pettengell, Hans E Johnsen, Ulrich Jaeger, Gregor Verhoef, Matthias Schwenkglenks, Pamela Bacon, Kate Bendall, Pieternella J Lugtenburg
JournalLeukemia research (Leuk Res) Vol. 36 Issue 5 Pg. 548-53 (May 2012) ISSN: 1873-5835 [Electronic] England
PMID22385870 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2012 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Granulocyte Colony-Stimulating Factor
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Antibodies, Monoclonal, Murine-Derived (adverse effects)
  • Antineoplastic Combined Chemotherapy Protocols (adverse effects)
  • Cyclophosphamide (adverse effects)
  • Doxorubicin (adverse effects)
  • Female
  • Granulocyte Colony-Stimulating Factor (therapeutic use)
  • Humans
  • Lymphoma, Large B-Cell, Diffuse (drug therapy)
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Neutropenia (chemically induced)
  • Prednisone (adverse effects)
  • Risk Assessment
  • Risk Factors
  • Rituximab
  • Vincristine (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: